A promising new study could provide an early warning system to enable people with epilepsy to know when they are at risk of having a seizure.
A Phase III study has shown that cannabidiol can reduce seizures by almost half in children with Dravet syndrome, a rare type of severe epilepsy.
Zebinix (eslicarbazepine acetate) has received market authorization as a once-daily monotherapy in adults with newly diagnosed partial-onset epilepsy.
Researchers observe clinically silent hippocampal seizures in two Alzheimer’s disease patients during sleep; a period critical for memory consolidation.
Research demonstrates a daily dose of cannabidiol may help reduce seizures in children and adults suffering from Lennox- Gastaut syndrome (LGS).
Authors also claim that stress-reduction techniques could be an effective low-risk treatment for sufferers.
Mark Stewart shares his group’s work on developing an appropriate small animal model for SUDEP, a condition that presents a significant challenge to researchers, particularly given that it occurs rarely and under circumstances where physiological data are seldom available
Recent findings have indicated that bumetanide could be used to block the formation of aberrant neural connections in the brain that form after a convulsive epileptic seizure.
Connections between Skywalker protein and brain lipids could be a target for the treatment of epilepsy
A collaborative study has revealed the structure and function of the ‘Skywalker’ protein in detail, identifying how its connections with certain lipids could be responsible for epileptic seizures.
Melodie Winawer discusses the how our growing knowledge of epilepsy genetics can be targeted in the development of new treatments, and the importance of collaborative research.